Annovis AD Phase II/III shows significant cognition improvement; PD topline due June 2024; Q1 cash $3.1M

Annovis Bio, Inc.

2024-Q1 EPS reported -$0.72

Q1 2024 cash $3.1M vs $5.8M at Dec 31, 2023; runway into Q4 2024. Operating expenses $7.8M (R&D $6.5M, G&A $1.3M).
Phase II/III AD: ADAS-Cog 11 improvement 3.3 pts vs 0.3 for placebo at 3 months; plan 18-month Phase III trial.
PD Phase III unblinded; topline results expected June 2024; 523 patients randomized, 471 completed.
Net loss per share $0.10 basic, $0.72 diluted; includes $6.7M non-cash gain from warrant revaluation.
Filed patent application for buntanetap in neuropsychiatric disorders including autism, ADHD, depression.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Annovis Bio, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 13, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-060518

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.